Khoo Chun Kheng, Vickery Christopher J, Forsyth Nicola, Vinall Nina S, Eyre-Brook Ian A
Department of Surgery, Musgrove Park Hospital, Taunton and Somerset NHS Trust, Taunton, UK.
Ann Surg. 2007 Jun;245(6):867-72. doi: 10.1097/01.sla.0000259219.08209.36.
A prospective randomized controlled trial (RCT) of multimodal perioperative management protocol in patients undergoing elective colorectal resection for cancer.
This study evaluates the use of a multimodal package in colorectal cancer surgery in the context of an RCT.
Patients for elective resection for colorectal cancer were offered trial entry. Participants were stratified by sex and requirement for a total mesorectal excision and centrally randomized. Multimodal patients received intravenous fluid restriction, unrestricted oral intake with prokinetic agents, early ambulation, and fixed regimen epidural analgesia. Control patients received intravenous fluids to prevent oliguria, restricted oral intake until return of bowel motility, and weaning regimen epidural analgesia. Adherence to both regimens was reinforced using a daily checklist and protocol guidance sheets. Discharge decision was made using pre-agreed criteria. The primary endpoint was postoperative stay, and achievement of independence milestones. Secondary endpoints were postoperative complications, readmission rates, and mortality. Analysis was by intention to treat.
Seventy patients were recruited. Approximately one fourth underwent TME. Median ages were similar (69.3 vs. 73.0 years). The median stay was significantly reduced in the multimodal group (5 vs. 7 days; P < 0.001, Mann-Whitney U test). Patients in the control arm were 2.5 times as likely to require a postoperative stay of more than 5 days. Patients in the multimodal group had less cardiorespiratory and anastomotic complications but more readmissions. There were 2 deaths, both controls.
This RCT provides level 1b evidence that a multimodal management protocol can significantly reduce postoperative stay following colorectal cancer surgery. Morbidity and mortality are not increased.
一项关于择期结直肠癌切除术患者围手术期多模式管理方案的前瞻性随机对照试验(RCT)。
本研究在随机对照试验的背景下评估多模式方案在结直肠癌手术中的应用。
邀请择期行结直肠癌切除术的患者参与试验。参与者按性别和直肠系膜全切除术需求进行分层,并进行中心随机分组。多模式组患者接受静脉液体限制、使用促动力剂时不限量口服、早期活动及固定方案的硬膜外镇痛。对照组患者接受静脉输液以预防少尿、在肠道蠕动恢复前限制口服摄入,并采用逐渐减量方案的硬膜外镇痛。通过每日检查表和方案指导表强化对两种方案的依从性。使用预先商定的标准做出出院决定。主要终点是术后住院时间和达到独立里程碑。次要终点是术后并发症、再入院率和死亡率。分析采用意向性分析。
招募了70名患者。约四分之一的患者接受了直肠系膜全切除术。中位年龄相似(69.3岁对73.0岁)。多模式组的中位住院时间显著缩短(5天对7天;P<0.001,曼-惠特尼U检验)。对照组患者术后住院时间超过5天的可能性是多模式组患者的2.5倍。多模式组患者的心肺和吻合口并发症较少,但再入院较多。有2例死亡,均为对照组患者。
这项随机对照试验提供了1b级证据,表明多模式管理方案可显著缩短结直肠癌手术后的住院时间。发病率和死亡率并未增加。